Skip to main content
OpenTrials
Completed

NCT Number: NCT03135535

Micro-mobile Foot Compression and Diabetic Foot

Diabetic foot ulceration (DFU) is a common and largely preventable complication. While most of these ulcers can be treated successfully, some will persist and become infected. Ultimately, nearly one fifth of patients with infected lower-extremity diabetic ulcers will require amputation of the affected limb.Prevention by identifying people at higher risk is the key for better clinical management of such patients. It is not uncommon for patients suffering from diabetes to have concomitant lower extremity edema or even venous insufficiency and they subsequently may benefit from graduated compression. However, because of the common association of peripheral arterial disease (PAD) in patients with diabetes, most clinicians are reluctant to apply compressive dressings in fear of exacerbating the symptoms of PAD and the possible resulting gangrene.

A novel micro-mobile foot compression device named Footbeat (AVEX, Inc.) offers alternative means providing lower extremity compression. This device is portable and can be used in a standard diabetic shoes on daily basis, which in turn may improve venous blood and relief from concomitant lower extremity edema. In addition, potential improvement in lower extremity blood flow in response to regular foot compression, could improve balance, gait, skin perfusion, plantar sensation, and overall daily physical activities (e.g. number of taken steps per day, duration of standing, etc).

The purpose of this study is to conduct an observational study with N=30 ambulatory patients with diabetes and loss of protective sensation to assess whether this micro-mobile foot compression device can help improving motor function, lower extremity perfusion, and vascular health.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Diabetic Foot Diabetic Neuropathies Endocrine System Diseases Foot Ulcer Foot Ulcer, Diabetic Glucose Metabolism Disorders Hemic and Lymphatic Diseases Leg Ulcer Lower Extremity Edema Lymphatic Diseases Metabolic Diseases Nervous System Diseases Neuritis Neuromuscular Diseases Neuropathy;Peripheral Nutritional and Metabolic Diseases PAD Peripheral Nervous System Diseases Skin Diseases Skin Ulcer Skin and Connective Tissue Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Baylor College of Medicine

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female , age 18 or older with the ability and willingness to provide Informed consent
  • Patient is willing to participate in all procedures and follow up evaluations necessary to complete the study
  • History of type 2 diabetes confirmed by patient's physician.
  • History of peripheral neurpathy .

Exclusion criteria

  • Patients with severe peripheral vascular disease (ankle-brachial systolic pressure index (ABI) <0.5 or ABI>1.30)
  • Patients with active wound infection, or untreated osteomyelitis
  • Patients with major foot deformities (e.g. Charcot Foot) or major amputation (e.g. above ankle)
  • Unamulatory of those who are unable to independently walk with or without walking assistance, a distance of 40 feet.
  • Patients who are unable or unwilling to participate in all procedures and follow up evaluations
  • Patients currently on immunosuppressive drugs.
  • Pregnant or breast feeding ladies.

Treatment and study plan

Avex Footbeat

Device

Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.

Primary outcomes

  1. Change in Balance From Baseline to 4 Weeks

    Time frame: baseline and 4 weeks.

    Balance will be quantified by measuring body sway in medial-lateral direction using a validated wearable sensors technology (Balansens, Biosensics LLC) and body sway change after 4-weeks of daily use of AVEX Footbeat will be assessed compare to baseline. Th unit of measurement is cm.

  2. Change in Skin Perfusion From Baseline to 4 Weeks

    Time frame: Baseline and 4 weeks

    Skin perfusion was quantified using Skin Perfusion Pressure Test (SPP) at the lower extremities at baseline and at 4-week (end point). The measurement of SPP was done using a device called Sensilase PAD-IQ (VASAMED). The unit of measurement is mmHg.

Secondary outcomes

  1. Change in Lower Extremity Edema From Baseline to 4 Weeks

    Time frame: Baseline and 4 weeks

    Edema will be measured by traditional circumference change of ankle. The unit of measurement is cm.

  2. Change in Plantar Sensation From Baseline to 4-week

    Time frame: Baseline to 4 weeks

    The change in plantar sensation after 4-weeks use of AVEX Footbeat will be assessed using vibratory perception threshold (VPT) test. The unit of this measurement is volt.

  3. Change in Stride Velocity From Baseline to 4-week

    Time frame: Baseline to 4 weeks

    The change in stride velocity was quantified by gait speed measured using a validated wearable sensor (LEGSys, Biosensics, LLC). The unit of measurement is meter per second (m/s)

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Avex LLC

Registry information

Official study title

Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation

Important dates

Study start
2017
Primary completion
2018
Study completion
2021
First posted
May 1, 2017
Registry last updated
Oct 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.